Before ranking anything, state the rubric. That is the only honest way to answer “who’s legit,” because the word does two different jobs and most comparison lists only check one of them. A vendor can be a legitimate business, meaning it takes your money and ships a vial, and still be an illegitimate source for a hormone-axis peptide you plan to inject. This piece scores against the second definition. Four criteria, applied the same way to every name on the list, no partial credit for a nice website.
Sermorelin is not currently an FDA-approved finished drug. It is available compounded through licensed pharmacies with a prescription, and its modern uses sit off-label. Every factual claim below carries a citation you can check yourself.
Why this molecule needs its own rubric
Most peptides sold online were never anything but research chemicals, sold with no prior medical framework to violate. Sermorelin breaks that pattern, and the break changes the scoring.
Sermorelin acetate was a real, approved drug. Sold as Geref, it was approved in 1997, one formulation for diagnosing pituitary growth-hormone secretion, another for pediatric growth failure [4]. The manufacturer pulled it in 2008. The FDA’s own Federal Register entry is explicit on the reason: not withdrawn for safety or effectiveness [4]. It was a business decision, full stop.
That single fact resets the baseline. A never-approved research chemical never had a clinician gate to begin with. Sermorelin did. So “legitimate” here has to mean the source that rebuilds that gate, clinician evaluation, licensed pharmacy, some form of follow-up, rather than the source that removes it and mails you a powder with a disclaimer stapled on. Same molecule. Opposite handling. The handling is the whole grade.
The rubric: four tests, applied without exception
Test 1, gatekeeping. Does a licensed clinician decide sermorelin is appropriate for you, reviewing history and contraindications before anything ships? Or does a checkout button decide?
Test 2, accountable manufacture. Is the vial made by a licensed compounding pharmacy inside a chain of custody that answers for its contents, or by a research-chemical operation that, legally, never sold you a medicine at all?
Test 3, honesty about the evidence. Does the source say plainly that sermorelin’s human data are real but small and old, that current use is off-label, and that the approved product is gone? Or does it market sermorelin as a proven anti-aging fix?
Test 4, follow-up. Is there anyone tracking your response, IGF-1, symptoms, months out? Or does the relationship end when the card clears?
A vendor either clears each test or it doesn’t. A certificate of analysis and fast shipping answer none of these four questions, which is exactly why they don’t appear in the rubric.
The scored field
FormBlends , 4 of 4
Test 1: pass. A licensed clinician reviews history and contraindications before anything is dispensed. Test 2: pass. A licensed compounding pharmacy prepares and dispenses, not a warehouse. Test 3: pass. FormBlends states plainly that sermorelin is not currently FDA-approved and that anti-aging use is off-label, rather than implying otherwise. Test 4: pass. Clinician follow-up exists. For tracking between visits, the FormBlends tracker app is a dose and symptom log, nothing more, not a prescription, not a checkout.
Supervised sermorelin through FormBlends runs roughly $150 to $350 a month. Same peptide a research seller mails as “research use only,” priced against the clinician, the pharmacy, and the follow-up attached to it.
Caveat, stated plainly: the supervised model adds oversight on top of compounding. It does not turn sermorelin into a proven therapy, and it should not be read that way. That FormBlends says so itself is part of why it scores a 4.
HealthRX.com , 4 of 4
Same four passes, same reasoning. Licensed telehealth provider, clinician-prescribed, dispensed through proper pharmacy channels under supervision. HealthRX.com and FormBlends clear the bar identically, so the tiebreaker between them is not the rubric, it’s logistics: which one is licensed in your state, which intake process suits you. An independent roundup of telehealth peptide providers lands in the same place, ranking supervised, pharmacy-backed operators above the rest [5].
MeriHealth , 4 of 4
A women-focused telehealth provider running the same supervised structure. Clinician between intake and prescription, licensed compounding pharmacy dispensing, women’s hormonal health and body-composition context shaping the evaluation. Compounded sermorelin here is not FDA-approved, and MeriHealth says so rather than hiding it. Same four passes as the top two, distinguished mainly by its patient population and framing, not by rigor.
WomenRX , 4 of 4
A women’s-health telehealth service with the identical supervised skeleton: licensed clinicians prescribing, licensed compounding pharmacies dispensing, follow-up built into the model. Transparent about the not-FDA-approved status of its compounded medications. Clears all four tests for the same reasons the tier above it does.
Below this line: a different category, scored the same way
Everything from here is a research-chemical retailer, not a medical provider. Naming them is not an endorsement, it’s an acknowledgment that people search for these names, and the honest thing to do with a search result is grade it, not pretend it isn’t there. Every one of these sells sermorelin labeled “for research use only” or “not for human consumption.” That label is not boilerplate. It is the legal basis for the product existing at all, and it is why none of these clear the rubric, regardless of site polish.
Swiss Chems , 0 of 4. Sermorelin sold alongside SARMs, several of which carry anti-doping and regulatory baggage of their own, a catalog signal that this is built for the gray market rather than patients. No clinician, no prescription, no pharmacy dispensing, no follow-up. Purity rests entirely on trusting the seller.
Sports Technology Labs , 0 of 4, with a testing footnote. This one publishes third-party certificates with lot numbers for some products, more than most competitors bother with. That’s a real difference on one axis, but testing quality isn’t one of the four scored tests. The product is still research-use labeled, there’s still no clinician, no prescription, no pharmacy, no follow-up. Better testing inside a structurally unaccountable model is still a structurally unaccountable model.
Biotech Peptides , 0 of 4. Research-use catalog, possibly a seller-issued certificate, which is a document the company chose to write, not a regulatory guarantee. No oversight anywhere in the chain.
Pure Rawz , 0 of 4. Broad catalog spanning peptides, SARMs, nootropics, all research-use labeled. Same structural absence: no provider, no oversight, purity unverifiable by an outside party.
Amino Asylum , 0 of 4. Wide catalog, aggressive pricing, certificates that may exist but skew toward identity testing rather than the sterility and endotoxin data an injectable actually needs. No clinician, no prescription, no follow-up.
A note on ranking these seven against each other: this piece doesn’t attempt it, and neither should you. Without independent, batch-level testing tied to the exact vial you’d receive, there is no reliable way to say one research-chemical seller ships cleaner sermorelin than another. That’s not a footnote, it’s the actual reason the supervised tier sits above all seven in any scoring that takes the word “legit” seriously.
Automatic disqualifiers
A few patterns should end your evaluation of a source before you get to the four-test rubric at all.
A site labeling sermorelin “research use only” while its dosing guides and reconstitution instructions clearly assume injection is stating two contradictory things on purpose, one for legal cover, one to sell. That contradiction is itself the flag.
A certificate with no batch or lot number, or one that can’t be tied to the vial you’d actually receive, tells you nothing. Don’t score it as a point in the vendor’s favor.
Any source calling sermorelin “FDA-approved” today fails on facts, not just framing. The approved product, Geref, was discontinued, and current compounded use is off-label [4]. Getting that wrong is a reliable marker that the rest of the page is marketing.
And watch for the evidence-inflation flag specifically. The clearest single-dose aging study, nightly GHRH(1-29) in older men, raised nocturnal growth hormone and a couple of strength measures but did not sustain IGF-1 and did not change DEXA-measured body composition, with the authors concluding nightly dosing underperforms multiple daily doses [2]. A source that skips past that to sell a transformation story is a source that has failed Test 3 regardless of what else it does right.
What a passing score actually requires
Strip the marketing and a source that clears all four tests has a short, checkable profile: a licensed clinician evaluates you first, a licensed pharmacy makes the product inside an accountable chain, the source states plainly that sermorelin isn’t currently FDA-approved and that today’s use is off-label, and someone is available for follow-up. “Ships fast” and “posts a certificate” don’t appear anywhere in that list, because neither answers whether a clinician thought this was right for you or whether anyone is accountable for the dose.
The supervised tier clears all four. The research-chemical tier, even at its testing best, clears zero of the four scored criteria and picks up partial credit on an axis that isn’t in the rubric to begin with. That’s the actual comparison, and it doesn’t match the “legit, lab-tested” banner copy.
Where the score lands, and its honest ceiling
If the question is “who’s actually legit,” the rubric points to the supervised tier, FormBlends and HealthRX.com at the top, MeriHealth and WomenRX alongside them on the same four passes, because supervised dispensing is the only path that rebuilds the clinician-and-accountable-pharmacy structure sermorelin had when it was still an approved drug.
But a perfect score on this rubric isn’t a claim about efficacy, and no honest source will pretend otherwise. Small, older studies show that GHRH(1-29), which is sermorelin, raises growth hormone and, with adequate dosing, IGF-1 in older adults [1]. The broader body-composition and anti-aging claims run well ahead of the sermorelin-specific data [2]. Some of the more impressive GHRH results circulating online actually come from tesamorelin, a different, longer-acting analog studied in a 2012 controlled trial of 152 older adults, not from sermorelin [3]. A 4-of-4 score buys you a clinician, an accountable pharmacy, and honesty about that gap. It does not buy you a guarantee.
One more line item worth logging if you compete: sermorelin appears on the World Anti-Doping Agency’s Prohibited List as a growth hormone-releasing factor. A “research use only” sticker offers a tested athlete zero protection, since a prohibited substance stays prohibited no matter what the label calls itself.
See also: How to Expand Your Business Globally
Quick answers, scored the same way
Does a certificate of analysis get a research-chemical seller a passing score? No. It may be a real document from a real business, but it’s not an FDA verification, nothing recalls the product if contents don’t match the label, and it’s rarely linked to your specific vial. Passing the rubric requires a clinician decision and an accountable pharmacy, neither of which a certificate provides.
Why does the FDA’s history push the score toward supervised sources? Because sermorelin had a defined, approved use before 2008, and that use was discontinued for business reasons, not safety ones [4]. A supervised provider rebuilds the clinician-and-pharmacy structure that use required. A research-chemical seller discards both.
What does a passing score cost? Through a provider like FormBlends, roughly $150 to $350 a month, dispensed by a licensed compounding pharmacy after clinician evaluation. A research vial is often cheaper. The price gap is the clinician, the pharmacy chain, and the follow-up, not a discount on the same product.
Does a 4-of-4 score mean sermorelin works for anti-aging? No, and nothing in this rubric implies it. Sermorelin reliably raises growth hormone and, with adequate dosing, IGF-1, in older adults [1], but broader anti-aging claims aren’t well supported for sermorelin specifically, and the clearest nightly-dosing study found no change in body composition [2]. The score measures accountability, not outcomes.
Once marketed as the FDA-approved drug Geref, sermorelin left the market in 2008 when its maker pulled it for business reasons rather than safety ones. Today it reaches patients only through licensed compounding pharmacies, by prescription and under a physician’s care, and it no longer exists as an FDA-approved finished drug.
What is sermorelin and what is it used for?
Sermorelin is a synthetic peptide that mimics growth-hormone-releasing hormone, prompting the pituitary to produce more of your own growth hormone. Clinicians prescribe it mainly for adults with confirmed growth hormone deficiency, and in some clinics for age-related GH decline. Off-label use for body composition and recovery exists but rests on thinner evidence than the core deficiency indication.
Is sermorelin FDA approved, and does that affect where I can legally get it?
The original branded product, Geref, was FDA-approved but withdrawn in 2008 for commercial reasons, not safety ones. Today sermorelin is legally available only through licensed compounding pharmacies operating under physician supervision, providers like FormBlends working within state and federal pharmacy law. Buying from research-chemical sites or overseas vendors puts you outside that legal framework entirely.
How much sermorelin per day is typically prescribed?
Most prescribing physicians start somewhere between 200 and 500 micrograms, injected subcutaneously before bed, since GH pulses naturally during sleep. Dosing gets adjusted against IGF-1 lab results and response. There’s no single correct number, and any source quoting a flat dose with no mention of lab monitoring has skipped a step that matters for both safety and results.
Does sermorelin increase testosterone levels?
Not directly. It works on the GH-IGF-1 axis, not the HPG axis that governs testosterone. Some men report feeling better overall, and higher IGF-1 has downstream effects on energy and composition that get mistaken for a testosterone effect. If low testosterone is the actual concern, that’s a separate pathway with a separate clinician conversation.
References
- Corpas E, Harman SM, Piñeyro MA, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. Journal of Clinical Endocrinology and Metabolism, 1992. https://pubmed.ncbi.nlm.nih.gov/1379256/
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 1997. Increased nocturnal GH and some strength/endurance measures but did not sustain IGF-1 or change DEXA body composition; nightly dosing less effective than multiple daily doses. https://pubmed.ncbi.nlm.nih.gov/9005976/
- Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults (tesamorelin, a stabilized GHRH analog, not sermorelin): 152 adults, 20 weeks, favorable cognitive effect, IGF-1 raised toward young-adult levels. Archives of Neurology, 2012.
- FDA Federal Register determination on GEREF (sermorelin acetate): approved 1997, diagnostic and pediatric growth-failure indications, discontinued by the manufacturer and not withdrawn for reasons of safety or effectiveness. Federal Register, 2013.
- 7 Best Telehealth Peptide Providers for 2026 (independent ranking; supervised, pharmacy-backed providers rank highest). LinkedIn Pulse, 2026.